

**Final Agenda**  
**57th meeting of the Committee for Risk Assessment**

**31 May-3 June**  
**and**  
**8-10 June 2021**

**Virtual meeting**

**31 May starts at 14.00**  
**10 June ends at 17:30**

***Times are Helsinki times***

**Item 1 – Welcome and Apologies**

**Item 2 – Adoption of the Agenda**

***RAC/A/57/2021***  
***For adoption***

**Item 3 – Declarations of conflicts of interest to the Agenda**

**Item 4 – Appointment of (co-)rapporteurs**

4.1. Appointment of (co-)rapporteurs for CLH dossiers, restriction dossiers, authorisation applications, evaluation of occupational exposure limits

***For agreement***  
***Closed session***

**Item 5 – Report from other ECHA bodies and activities**

5.1. RAC Work Plan for all processes

***For information***

5.2. CLH: Procedure for agreement seeking

***For agreement***  
***RAC/57/2021/01***

## **Item 6 – Requests under Article 77(3)(c)**

6.1. Classification for environmental toxicity of lead

***For discussion and adoption***

## **Item 7 – Health based exposure limits at the workplace**

7.1 Adoption of opinions: Asbestos – final draft opinion

***For discussion and adoption***

## **Item 8 – Harmonised classification and labelling (CLH)**

**8.1. Report from the 27/28 April 2021 RAC CLH WG**

***For information/discussion***

***RAC/57/2021/02***

***(RAC WG/CLH/R/1/2021)***

**8.2. CLH dossiers**

**8.2.1 Hazard classes for agreement without plenary debate**

- Reaction mass of 1-(2,3-epoxypropoxy)-2,2-bis ((2,3-epoxypropoxy)methyl) butane and 1-(2,3-epoxypropoxy)-2-((2,3-epoxypropoxy)methyl)-2-hydroxymethyl butane (EC: -; CAS: -): germ cell mutagenicity, reproductive toxicity (*discussed in the CLH WG*)
- Sodium chlorate (EC: 231-887-4; CAS: 7775-09-9): acute oral toxicity, hazardous to the aquatic environment (*discussed in the CLH WG*)
- Potassium chlorate (EC: 223-289-7; CAS: 3811-04-9): acute oral and inhalation toxicity, hazardous to the aquatic environment (*discussed in the CLH WG*)
- Triethylamine (EC: 204-469-4; CAS: 121-44-8): acute inhalation and dermal toxicity, serious eye damage/eye irritation (*discussed in the CLH WG*)
- Di-n-butylamine (EC: 203-921-8; CAS: 111-92-2): acute oral, dermal and inhalation toxicity, skin corrosion/irritation, serious eye damage/eye irritation, STOT SE (*discussed in the CLH WG*)
- Difenoconazole (ISO): physical hazards, acute dermal and inhalation toxicity, skin sensitisation, skin corrosion/irritation, serious eye damage/eye irritation, germ cell mutagenicity, STOT SE, hazardous to the aquatic environment
- 4-Nitrosomorpholine: carcinogenicity
- N,N-dimethyl-p-toluidine: acute toxicity via all routes, germ cell mutagenicity

- Metribuzin (ISO): acute toxicity via all routes, skin irritation, serious eye damage/eye irritation, respiratory sensitisation, skin sensitisation, germ cell mutagenicity, carcinogenicity, reproductive toxicity, STOT SE
- Lithium carbonate; lithium chloride; lithium hydroxide: germ cell mutagenicity, carcinogenicity

## 8.2.2 Hazard classes for agreement with plenary debate

- 8.2.2.1 Reaction mass of 1-(2,3-epoxypropoxy)-2,2-bis ((2,3-epoxypropoxy)methyl) butane and 1-(2,3-epoxypropoxy)-2-((2,3-epoxypropoxy)methyl)-2-hydroxymethyl butane (EC: -; CAS: -) – *developmental toxicity*
- 8.2.2.2 Triethylamine (EC: 204-469-4; CAS: 121-44-8) – *acute oral toxicity*
- 8.2.2.3. Difenoconazole (ISO); 1-({2-[2-chloro-4-(4-chlorophenoxy)phenyl]-4-methyl-1,3-dioxolan-2-yl)methyl)-1*H*-1,2,4-triazole; 3-chloro-4-[(2*RS*,4*RS*;2*RS*,4*SR*)-4-methyl-2-(1*H*-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-2-yl]phenyl 4-chlorophenyl ether (EC 601-613-1; CAS 119446-68-3)
- 8.2.2.4. 4-Nitrosomorpholine (EC: 627-564-6; CAS: 59-89-2)
- 8.2.2.5. N,N-dimethyl-*p*-toluidine (EC: 202-805-4; CAS: 99-97-8)
- 8.2.2.6. Metribuzin (ISO); 4-amino-6-tert-butyl-3-methylthio-1,2,4-triazin-5(4*H*)-one; 4-amino-4,5-dihydro-6-(1,1-dimethylethyl)-3-methylthio-1,2,4-triazin-5-one (EC: 244-209-7; CAS: 21087-64-9)
- 8.2.2.7. [1] Lithium carbonate; [2] lithium chloride; [3] lithium hydroxide (EC: [1] 209-062-5; [2] 231-212-3; [3] 215-183-4; CAS: [1] 554-13-2; [2] 7447-41-8; [3] 1310-65-)
- 8.2.2.8. Nonylphenol, branched and linear, ethoxylated (with average molecular weight < 352 g/mol) [includes ortho-, meta-, para- isomers or any combination thereof] (EC: 500-315-8; 500-024-6; 500-045-0; 500-209-1; 248-762-5; 243-816-4; 248-291-5; and others; CAS: 127087-87-0; 9016-45-9; 26027-38-3; 68412-54-4; 27986-36-3; 20427-84-3; 27176-93-8; 1119449-38-5 and others)
- 8.2.2.9. Nonylphenol, branched and linear, ethoxylated (with 352 g/mol ≤ average molecular weight < 704 g/mol) [includes ortho-, meta-, para- isomers or any combination thereof] (EC: 230-770-5; 248-743-1; 247-555-7; 248-293-6 and others; CAS: 127087-87-0; 9016-45-9; 7311-27-5; 27942-27-4; 26264-02-8; 27177-05-5; 14409-72-4 and others)
- 8.2.2.10. Nonylphenol, branched and linear, ethoxylated (with 704 g/mol ≤ average molecular weight ≤ 1540 g/mol) [includes ortho-, meta-, para- isomers or any combination thereof] (EC: -; CAS: 127087-87-0; 9016-45-9 and others)

***For discussion and adoption***

## Item 9 – Restrictions

### 9.1 General restriction issues

- 9.1.1. Framework for RAC and SEAC in checking conformity and developing opinions on restriction proposals

***For information/discussion***

- 9.1.2. Update on the Restrictions Task Force meeting (29/4)

***For information/discussion***

- 9.1.3. Report from the 11/12 May 2021 RAC REST WG

***RAC/57/2021/03***

***(RAC WG/REST/R/1/2021)***

***For information/discussion***

### 9.2 Restriction Annex XV dossiers

- 9.2.1 Conformity check and key issues discussion

- 9.2.1.1 1,6,7,8,9,14,15,16,17,17,18,18-Dodecachloropentacyclo-  
[12.2.1.1<sup>6,9,02,13,05,10</sup>]octadeca-7,15-diene ("Dechlorane  
Plus"<sup>TM</sup>)

***For discussion and agreement***

- 9.2.2 Opinion development

- 9.2.2.1 Undecafluorohexanoic acid (PFHxA), its salts and related substances – fourth draft opinion

***For discussion and adoption***

- 9.2.2.2 Substances in single-use baby diapers – second draft opinion

***For discussion/agreement***

- 9.2.2.3 Lead and its compounds in ammunition and fishing tackles – first draft opinion

***For discussion/agreement***

## Item 10 – Authorisation

### 10.1 General authorisation issues

- 10.1.1. Update on incoming/future applications

***For information/discussion***

- 10.1.2. Report from RAC WG on AfAs during May 2021 meeting

***For information/discussion***

***RAC/57/2021/04***

10.1.3. Update of the opinion format

***For information/discussion***

10.1.4. Evaluation of review reports

***For information/discussion***

***RAC/57/2021/05***

## **10.2 Authorisation applications**

10.2.1. Discussion on key issues

10.2.1.1. 5 applications for authorisation (chromium trioxide, chromic acid, dichromium tris(chromate))) from February 2021 submission window

***For discussion***

## **10.3 Agreement on draft opinions**

### **10.3.1. Draft opinions for agreement without plenary debate (A-list)**

10.3.1.1 218\_CT\_DOURECA (2 uses)

10.3.1.2 219\_CT\_HusqvarnaAB (1 use)

10.3.1.3 220\_CT\_SRG Global (2 uses)

10.3.1.4 225\_MOCA\_Luc (2 uses)

10.3.1.5 226\_OPE\_LETI (1 use)

### **10.3.2. Draft opinions for agreement with plenary debate**

10.3.2.1. 221\_CT\_SD\_USSK (1 use)

10.3.2.2. 222\_RR1\_SD\_Colle (1 use)

10.3.2.3. 223\_RR1\_EDC\_Lanxess (1 use)

10.3.2.4. 224\_RR1\_EDC\_Eurenco (1 use)

***For discussion and agreement***

## **10.4 Adoption of opinions**

10.4.1. 196\_OPE\_Becton (1 use)

10.4.2. 198\_OPE\_Zoetis (4 uses; comments on Use 4 only)

10.4.3. 199\_OPE\_Biokit (2 uses; comments on Use 2 only)

10.4.4. 203\_OPE\_NPE\_Qiagen (4 uses)

***For discussion and adoption***

## **Item 11 – AOB**

11.1. Update form the ECHA legal services on the current legal cases

***For information***

## **Item 12 – Minutes of RAC-57**

12.1 Table with Summary Record of the Proceedings, and Conclusions and Action points from RAC-57

***For adoption***

## **PROVISIONAL TIMELINE FOR THE DISCUSSIONS AT RAC-57 – WEEK 1**

Please note that this timeline is provisional. Changes can be made before and during the meeting in order to accommodate the discussions.

### **Monday 31 May 2021: Afternoon session**

- Item 1 – Welcome and Apologies
- Item 2 – Adoption of the Agenda
- Item 3 – Declarations of conflicts of interest to the Agenda
- Item 5 – RAC Work Plan for Restriction, Authorisation and C&L processes
- Item 11 – AOB
- Item 7 – OEL

### **Tuesday 1 June 2021: Morning session**

- Item 9 – Restrictions

### **Tuesday 1 June 2021: Afternoon session**

- Item 7 – OEL
- Item 9 – Restrictions

### **Wednesday 2 June 2021: Morning session**

- Item 9 – Restrictions

### **Wednesday 2 June 2021: Afternoon session**

- Item 9 – Restrictions
- Item 10 – Authorisation applications

### **Thursday 3 June 2021: Morning session**

- Item 10 – Authorisation applications

### **Thursday 3 June 2021: Afternoon session**

- Item 10 – Authorisation applications
- Item 12 – RAC-57A Summary Record adoption

## **PROVISIONAL TIMELINE FOR THE DISCUSSIONS AT RAC-57 – WEEK 2**

Please note that this timeline is provisional. Changes can be made before and during the meeting in order to accommodate the discussions.

### **Tuesday 8 June 2021: Morning session**

- Item 1 – Welcome and Apologies
- Item 3 – Declarations of conflicts of interest to the Agenda
- Item 8 – CLH dossiers
- Item 6 – Art. 77(3)c

### **Tuesday 8 June 2021: Afternoon session**

- Item 8 – CLH dossiers

### **Wednesday 9 June 2021: Morning session**

- Item 8 – CLH dossiers

### **Wednesday 9 June 2021: Afternoon session**

- Item 8 – CLH dossiers

### **Thursday 10 June 2021: Morning session**

- Item 8 – CLH dossiers

### **Thursday 10 June 2021: Afternoon session**

- Item 8 – CLH dossiers
- Item 6 – Art. 77(3)c
- Item 11 – AOB
- Item 12 – RAC-57A Summary Record adoption
- Item 4 – Appointment of rapporteurs

*Social event (optional)*

\*\*\*